January 3, 2014
Alzheimer’s disease treatments have been shown to be safe and have some positive effect when tested in animal models. However, many of these potentially successful drugs have not been brought to human trials because of the increased cost and risk.
The Alzheimer’s Drug Discovery Foundation is responding to this problem through the Program to Accelerate Clinical Trials, an initiative to increase the number of innovative drugs tested in humans for Alzheimer’s disease, related dementias, and cognitive aging.
The program will fund biomarker-based pilot clinical trials for Alzheimer’s disease and in some cases will also support Phase I safety testing and IND-enabling studies to accelerate new drugs into trials. ADDF also is interested in supporting targeted pharmacological and non-pharmacological approaches to prevention and clinical biomarker development programs.
ADDF is particularly interested in projects to test drugs approved for other indications in Alzheimer’s disease clinical trials, as well and therapies that address the following targets: energy utilization/mitochondria function, insulin sensitivity, protein degradation/autophagy, ApoE function and cholesterol metabolism, vesicular trafficking, inflammatory pathways, synaptic function/morphology, calcium regulation, myelin changes, ischemia and oxidative stress, vascular injury, and the blood-brain barrier interface.
Grants of up to $1.5 million will be awarded to selected projects.
Applications may be submitted by nonprofit academic institutions and for-profit biotechnology companies, both public and private, around the world.
In 2014, ADDF will be accepting applications on a quarterly basis (March 5, June 5, September 5, and December 5). A Letter of Intent is due two weeks prior to each deadline.
For complete program guidelines and application procedures, see the ADDF Web site.